Nymox Pharmaceutical Corporation
NYMXF
$0.0751
-$0.0049-6.13%
OTC PK
| 12/31/2024 | 09/30/2024 | 12/31/2023 | 12/31/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -857.00K | -- | -5.31M | -5.31M | -1.11M |
| Total Depreciation and Amortization | 0.00 | -- | 11.00K | 12.30K | 56.70K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 159.00K | -- | 3.68M | 3.68M | 33.30K |
| Change in Net Operating Assets | -19.00K | -- | 719.00K | 719.00K | 111.00K |
| Cash from Operations | -717.00K | -- | -897.00K | -897.00K | -909.00K |
| Capital Expenditure | -- | -- | 0.00 | 0.00 | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 0.00 | 0.00 | 0.00 |
| Total Debt Issued | 2.67M | -- | 750.00K | 750.00K | 750.00K |
| Total Debt Repaid | -64.00K | -- | -9.00K | 991.00K | -60.00K |
| Issuance of Common Stock | -- | -- | 150.00K | -- | -- |
| Repurchase of Common Stock | -1.86M | -- | -- | -850.00K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 750.00K | -- | 891.00K | 891.00K | 690.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 33.00K | -- | -6.00K | -6.00K | -219.00K |